Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants

Sleep Research Online

Volumn 1, Issue 1, 1998, Pages 49-61

  Nishino, Seiji ^a,b   Mao, Julie ^a   Sampathkumaran, Raghavan ^a   Shelton, Jeff ^a   Mignot, Emmanuel ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; NORADRENALIN; SEROTONIN UPTAKE INHIBITOR;

ANIMAL; ARTICLE; DOG; DOSE RESPONSE; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; NARCOLEPSY; REM SLEEP; SLEEP; WAKEFULNESS;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOGS; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; NARCOLEPSY; NOREPINEPHRINE; SEROTONIN UPTAKE INHIBITORS; SLEEP; SLEEP, REM; WAKEFULNESS;

EID: 0032229802     PISSN: 1096214X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Akindele MO, Evans JI, Oswald I. Mono-amine oxidase inhibitors, sleep and mood. Electroencephalogr Clin Neurophysiol 1970; 29: 47-56.
2. Aldrich MS. Narcolepsy. Neurology 1992; 42: 34-43.
3. Aston-Jones G, Bloom FE. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci 1981; 1: 876-86.
4. Baker TL, Dement WC. Canine narcolepsy-cataplexy syndrome: evidence for an inherited monoaminergic-cholinergic imbalance. In: McGinty DJ, Drucker-Colín R, Morrison A, Parmeggiani PL, eds. Brain Mechanisms of Sleep. New York: Raven Press, 1985, pp. 199-233.
5. Baldessarini RJI. Pharmacology of the amphetamine. Pediatrics 1972; 49: 694-701.
6. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiat 1988; 12: 695-700.
7. Besset A, Tafti M, Villemine E, Billiard M. Effect du modafinil (300mg) sur le sommeil, la somnolence et la vigilance du narcoleptique. Neurophysiol Clin 1993; 23: 47-60.
8. Boivin DB, Montplaisir J, Petit D, Lambert C, Lubin S. Effect of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol 1993; 16: 46-53.
9. Brown RM, Goldman PS. Catecholamines in neocortex of rhesus monkeys: regional distribution and ontogenetic development. Brain Res 1977; 142: 576-80.
10. Charnay Y, Leger L, Vallet PG, Hof PR, Jouvet M, Bouras C. [3H]nisoxetine binding sites in the cat brain: an autoradiographic study. Neurosci 1995; 69: 259-70.
11. Ciliax BJ, Heilman C, Demchyshyn LL, Pristupa ZB, Ince E, Hersch SM, Niznik HB, Levey AI. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1995; 15: 1714-23.
12. Edgar DM, Seidel WF, Contreras P, Vaught JL, Dement WC. Modafinil promotes EEG wake without intensifying motor activity in the rat. Canadian Journal Physiology and Pharmacology 1994; 72, S1: 362.
13. El Mansari M, Sakai K, Jouvet M. Unitary characteristics of presumptive cholinergic tegmental neurons during the sleep-waking cycle in freely moving cats. Exp Brain Res 1989; 76: 519-29.
14. Gillin JC, Horwitz D, Wyatt RJ. Pharmacologic studies of narcolepsy involving serotonin, acetylcholine, and monoamine oxidase. In: Guilleminault C, Dement WC, Passouant P, eds. Narcolepsy (Advances in Sleep Research Vol. 3). New York: Spectrum Publications, 1976, pp. 585-603.
15. Guilleminault C. Narcolepsy syndrome. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. Philadelphia: W.B. Saunders Company, 1994 pp. 549-61.
16. Hobson JA. Sleep and dreaming. J Neurosci 1990; 10: 317-82.
17. Hobson JA, McCarley RW, Wyzinski PW. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. Science 1975; 189: 55-8.
18. Honda K, Nishino S, Riehl J, Fang F, Mignot E. Local perfusion of dopamine D3 agonists in the substantia nigra aggravates cataplexy, but does not modulate sleep in canine narcolepsy. Sleep 1998 (in press).
19. Jones BE. Basic mechanism of sleep-wake states. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. Philadelphia: W.B. Saunders Company, 1994, pp. 145-62.
20. Kafi S, Gaillard JM. Brain dopamine receptors and sleep in the rat: effects of stimulation and blockade. Eur J Pharmacol 1976; 38: 357-63.
21. Kayama Y, Ohta M, Jodo E. Firing of 'possibly' cholinergic neurons in the rat laterodorsal tegmental nucleus during sleep and wakefulness. Brain Res 1992; 569: 210-20.
22. Koob GF, Swerdlow NR. The functional output of the mesolimbic dopamine system. In: Kalivas PW, Nemeroff CB, eds. The mesocorticolimbic dopamine system. New York: Acad Sci, 1988, pp. 216-27.
23. Kovacevic R, Radulovacki M. Monoamine changes in the brain of cats during slow-wave sleep. Science 1976; 193: 1025-7.
24. Koyama Y, Kayama Y Mutual interactions among cholinergic, noradrenaergic and serotonergic neurons studied by iontophoresis of these transmitters in rat brainstem nuclei. Neuroscience 1993; 55: 1117-26.
25. McPherson GA. Analysis of radioligand binding experiments: a collection of computer programs for IBM PC. J Pharmacol Meth 1985; 14: 213-28.
26. Mereu GP, Scarnati E, Paglietti E, Pellegrini Quarantotti B, Chessa P, DiChiara G, Gessa GL. Sleep induced by low doses of apomorphine in rats. Electroencephalogr Clin Neurophysiol 1978; 46: 214-9.
27. Mignot E, Guilleminault C, Dement WC, Grumet C. Genetically determined animal models of narcolepsy, a disorder of REM sleep. In: Driscoll P, ed. Genetically-Defined Animal Models of Neurobehavioral Dysfunction. Cambridge, MA: Birkhauser Boston Inc., 1992, pp. 90-110.
28. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994; 17: 436-7.
29. Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology 1993; 113: 76-82.
30. Miller JD, Farber J, Gatz P, Roffwarg H, German DC. Activity of mesencephalic dopamine and non-dopamine neurons across stages of sleep and waking in the rat. Brain Res 1983; 273: 133-41.
31. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. Sleep 1994; 17: 352-71.
32. Mitler MM, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. J Clin Neurophysiol 1990; 7: 93-118.
33. Munson PJ, Rodbard D. LIGAND; a versatile computerized approach for characterization of ligand-binding system. Anal Biochem 1980; 107: 220-39.
34. Nishino S, Arrigoni J, Shelton J, Dement WC, Mignot E. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep 1993; 16: 706-12.
35. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997; 52: 27-78.
36. Nishino S, Reid M, Dement WC, Mignot E. Neuropharmacology and neurochemistry of canine narcolepsy. Sleep 1994; 17: S84-S92.
37. Nishino S, Tafti M, Reid MS, Shelton J, Siegel JM, Dement WC, Mignot E. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of narcolepsy. J Neurosci 1995; 15: 4806-14.
38. Nissbrandt N, Engberg G, Pileblad E. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forbrain, cortical hemisheres and substantia nigra. Naunyn-Schmiedeberg's Arch Pharmacol 1991; 344: 16-28.
39. Ogren SO, Archer T, Johansson C. Evidence for noradrenergic involvement in the locomotor stimulant effects of amphetamine in the rat. Neurosci Lett 1983; 43: 327-31.
40. Parkes JD. Amphetamines and other drugs. In: Parkes JD. Sleep and its disorders. London: W.B. Saunders Company, 1985a, pp. 459-82.
41. Parkes JD. Daytime drowsiness. In: Parkes JD. Sleep and Its Disorders. London: WB Saunders , 1985b, pp. 267-334.
42. Parkes JD, Baraitser M, Marsden CD, Asselman P. Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neurol Scand 1975; 52: 337-53.
43. Reid MS, Siegel JM, Dement WC, Mignot E. Cholinergic mechanisms in canine narcolepsy: II. Acetylcholine release in the potine reticular formation is enhanced during cataplexy. Neuroscience 1994a; 59: 523-30.
44. Reid MS, Tafti M, Geary J, Nishino S, Siegel JM, Dement W C, Mignot E. Cholinergic mechanisms in canine narcolepsy: I. Modulation of cataplexy via local drug administration into pontine reticular formation. Neuroscience 1994b; 59: 511-22.
45. Reid MS, Tafti M, Nishino S, Sampathkumaran R, Siegel JM, Dement WC, Mignot E. Local administration of dopaminergic drugs into the ventral tegmental area modulate cataplexy in the narcoleptic canine. Brain Res 1996; 733: 83-100.
46. Scherschlicht R, Pole P, Schneeberger J, Steiner M, Haefely W Selective supression of rapid eye movement sleep (REMS) in cats by typical and atypical antidepressants. Advances in Biochemical Psychopharmacology 1982; 31: 359-64.
47. Schneeberger PJ, Haefely W Effects of several centrally active drugs on the sleep-wakefulness cycle of cats. Neuropharmacology 1979; 18: 259-67.
48. Seidel WF, Dement WC, Edgar DM. NonREM-sleep recovery in rats after various wake-promoting agents. Sleep Research 1996; 25: 478.
49. Shelton J, Nishino S, Vaught J, Dement WC, Mignot E. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995; 18: 817-26.
50. Steinfels GF, Heym J, Strecker RE, Jacobs BL. Response of dopaminergic neurons in cat to auditory stimuli presented across the sleep-waking cycle. Brain Res 1983; 277: 150-4.
51. Steriade M, Datta S, Pare D, Oakson G, Curro Dossi RC. Neuronal activities in brain-stem cholinergic nuclei related to tonic activation processes in thalamocortical systems. J Neurosci 1990; 10: 2541-59.
52. Taylor JR, Robbins TW. Enhanced behavioral control by conditioned reinforcers following microinjections of d-amphetamine into the nucleus accumbens. Psychopharmacology 1984; 84: 405-12.
53. Thorpy MJ, Goswami M. Treatment of narcolepsy. In: Thorpy MJ, ed. Handbook of Sleep Disorders. New York: Marcel Dekker, Inc. , 1990, pp. 235-58.
54. Trulson ME. Simultaneous recording of substantia nigra neurons and voltammetric release of dopamine in the caudate of behaving cats. Brain Res Bull 1985; 15: 221-3.
55. Villablanca JR, Marcus RJ, Olmstead CE. Effects of caudate nuclei or frontal cortex ablations in cats. II. sleep-wakefulness, EEG, and motor activity. Exp Neurol 1976; 53: 31-50.
56. Wiegand M, Moller AA, Lauer CJ, Stolz S, Schreiber W, Dose M, Krieg JC. Nocturnal sleep in Huntington's disease. J Neurol 1991; 238: 203-8.
57. Williams JA, Reiner PB. Noradrenaline hyperpolarizes identified rat mesopontine cholinergic neurons in vitro. J Neurosci 1993; 13: 3878-83.
58. Wu M, Gukyani S, Mignot E, Siegel J. Activity of REM-off cells during cataplexy in the narcoleptic dog. Sleep Res 1996; 25: 40.